Life Sciences

Basilea spends $2 million to acquire clinical-stage ant...

Basilea Pharmaceutica is embarking on its second endeavor to bolster its anti-in...

Siemens Healthineers & Qure.ai partnership Aims to Enha...

Siemens Healthineers, in collaboration with Qure.ai and the Global Fund to Comba...

Nkarta’s Landmark FDA Approval Propels Expansion of Cel...

Nkarta has achieved a significant milestone by securing FDA approval to broaden ...

Gilead to invest $100 million in Assembly Bio in return...

In a strategic maneuver aimed at revitalizing Assembly Biosciences, a biotech fi...

Novo Nordisk’s Strategic Move to Acquire KBP Bioscience...

Novo Nordisk, a global pharmaceutical giant renowned for its groundbreaking diab...

Roche’s Fenebrutinib Breakthrough in Multiple Sclerosis...

In a phase 2 study focused on multiple sclerosis (MS), Roche’s BTK inhibitor, Fe...

Omeros discontinues renal disease phase 3 treatment pos...

Omeros has discontinued a phase 3 trial involving narsoplimab for kidney disease...

Roche’s Spark Joins Forces with SpliceBio for Innovativ...

Roche’s gene therapy arm, Spark, has made a significant stride in bolstering its...

Ultragenyx and Mereo’s Genetic Treatment Slashes Bone F...

In a significant breakthrough, Ultragenyx and Mereo’s genetic bone disease treat...

Philips Launches New Platform to Improve Health Monitoring

Over two years following the acquisition of the medical information aggregator C...

After a 5-month hold FDA finally clears PepGen’s myoton...

PepGen’s achievement in receiving FDA clearance to proceed with the phase 1 stud...

Labcorp Unveils Breakthrough Blood Test for Alzheimer’s...

Labcorp has introduced a novel blood test aimed at aiding the diagnosis of Alzhe...

Merck’s Keytruda achieves overall survival goals in ear...

The initial perception of a complex treatment landscape in the early stages of n...

$15 Million Investment to Compete in the Eczema Challen...

Ichnos Sciences has, at last, found a potential buyer for its OX40 eczema ventur...

FDA Rejects Alnylam’s Expanded Approval Request for RNA...

The FDA has declined Alnylam Pharmaceuticals’ request to expand the approval of ...

BMS to acquire Mirati in a bid to diversify oncology po...

Bristol Myers Squibb (BMS) is set to make a substantial entry into the field of ...